These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8764567)

  • 21. Study of the idiotypic response to autoantibody to the alternative pathway C3/C5 convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals.
    Spitzer RE; Stitzel AE; Tsokos GC
    Clin Immunol Immunopathol; 1992 Mar; 62(3):291-4. PubMed ID: 1541054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C3 nephritic factor and mesangiocapillary glomerulonephritis.
    Williams DG
    Pediatr Nephrol; 1997 Feb; 11(1):96-8. PubMed ID: 9035182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibody to the alternative pathway C3/C5 convertase and its anti-idiotypic response. A study in affinity.
    Spitzer RE; Stitzel AE; Tsokos GC
    J Immunol; 1992 Jan; 148(1):137-41. PubMed ID: 1727863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-factor B autoantibody in dense deposit disease.
    Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
    Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating complement levels and C3 glomerulopathy.
    Fervenza FC; Sethi S
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1829-31. PubMed ID: 25341723
    [No Abstract]   [Full Text] [Related]  

  • 27. Hypocomplementaemia in a newborn caused by transplacental passage of maternal autoantibody with C3 nephritic factor (C3 NeF) activity.
    Weiss L; Rougier N; Blouin J; Kazatchkine MD; Lhotta K; König P
    Nephrol Dial Transplant; 1995 Dec; 10(12):2374. PubMed ID: 8808251
    [No Abstract]   [Full Text] [Related]  

  • 28. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production.
    Spitzer RE; Stitzel AE; Tsokos G
    Clin Immunol Immunopathol; 1992 Sep; 64(3):177-83. PubMed ID: 1386563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Complement activating factors in hypocomplementemic membranoproliferative glomerulonephritis (MPGN) patients' sera--comparison with C3NeF positive and negative cases].
    Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M
    Nihon Jinzo Gakkai Shi; 1987 Apr; 29(4):493-8. PubMed ID: 3656707
    [No Abstract]   [Full Text] [Related]  

  • 31. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
    Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel ELISA assay for the detection of C3 nephritic factor.
    Seino J; vd Wall Bake WL; van Es LA; Daha MR
    J Immunol Methods; 1993 Feb; 159(1-2):221-7. PubMed ID: 8445254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
    Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
    Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological features of patients affected by Barraquer-Simons syndrome.
    Corvillo F; Ceccarini G; Nozal P; Magno S; Pelosini C; Garrido S; López-Lera A; Moraru M; Vilches C; Fornaciari S; Gabbriellini S; Santini F; Araújo-Vilar D; López-Trascasa M
    Orphanet J Rare Dis; 2020 Jan; 15(1):9. PubMed ID: 31924231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity.
    Frémeaux-Bacchi V; Weiss L; Demouchy C; May A; Palomera S; Kazatchkine MD
    Nephrol Dial Transplant; 1994; 9(12):1747-50. PubMed ID: 7708258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C3 concentrations can be normal in patients with C3 glomerulopathy secondary to C3 nephritic factor.
    Anderson H; Van Voorthuizen M; O'Donnell J; Beck S
    J Clin Pathol; 2024 Jun; 77(7):503-506. PubMed ID: 38538072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
    West CD; McAdams AJ
    Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the origin and control of C3NeF.
    Spitzer RE; Stitzel AE
    In Vivo; 1988; 2(1):79-81. PubMed ID: 2979821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [An approach to research on nephritic factor and membranoproliferative glomerulonephritis].
    Ohi H
    Nihon Jinzo Gakkai Shi; 2012; 54(7):1006-15. PubMed ID: 23234212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.
    Clardy CW; Forristal J; Strife CF; West CD
    Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.